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Mammalian group IIA phospholipase A2 (PLA2) is be-
lieved to play important roles in inflammation, cell in-
jury, and tumor resistance. However, the cellular site of
action has not been clearly defined as it has long been
recognized that group IIA PLA2 is both a secretory and
mitochondrial protein. The purpose of this study was to
determine the subcellular target of the group IIA PLA2
and its role in apoptosis stimulated by growth factor
withdrawal. Cloning of the rat liver group IIA PLA2
demonstrated a typical secretory signal and no alterna-
tive splicing of the primary transcript. When a sequence
including the signal peptide and first 8 residues in the
mature enzyme or the entire PLA2 (including the signal
peptide) was fused to enhanced green fluorescent pro-
tein, the fusion protein was directed to the secretory
pathway rather than mitochondria in baby hamster kid-
ney (BHK) cells. To examine the role of group IIA PLA2
in cell injury, wild type (wt) rat group IIA PLA2 and a
mutant group IIA PLA2 containing a His-47 3 Gln mu-
tation (at the catalytic center) were transfected into
BHK cells and cells stably expressing these constructs
were isolated. After deprivation of growth factors, both
normal BHK cells and BHK cells expressing mutant
PLA2 underwent massive apoptosis, while BHK cells ex-
pressing wt PLA2 showed considerable resistance to
growth factor withdrawal-induced apoptosis. The secre-
tory PLA2 inhibitors 12-epi-scalaradial and aristolochic
acid abrogated resistance to apoptosis in the wt PLA2
expressing cells. These two inhibitors did not induce cell
death in the presence of fetal bovine serum, suggesting
that they induce cell death by blocking PLA2 generated
survival signals. This study demonstrates that group IIA
PLA2 generates anti-apoptotic survival signals in BHK
cells targeting the secretory pathway, and suggests that
high levels of group IIA PLA2 accumulated at inflamma-
tory sites may not only regulate inflammation, but also
may protect cells from unnecessary death induced by
pro-inflammatory agents.
Mammalian group IIA phospholipase A2 (PLA2)
1 catalyzes
the release of sn-2 fatty acid from membrane phospholipids.
This reaction produces arachidonic acid (AA) and lysophospha-
tidic acid (LPA) (1–5), both of which are multifunctional lipid
mediators. Group IIA PLA2 also has anti-bacterial activity and
functions as a modifier of tumor multiplicity (6–8). In addition
to being a secretory/plasma membrane-associated protein (9),
group IIA PLA2 has been isolated from purified mitochondria
(10–13), and has been suggested to be localized at inner and
outer membrane contact sites (14). Sequence analysis of this
mitochondrial group IIA PLA2 reveals the protein to be nearly
identical to the mature secretory enzyme (15), indicating that
the pre-protein of mitochondrial group IIA PLA2 is likely proc-
essed at the exactly the same site as the secretory group IIA
PLA2. As discussed in a recent review, mitochondria are
thought to be a target of group IIA PLA2 (2). Using PLA2
inhibitors and antisense oligonucleotides specific for group IIA
PLA2, we found that group IIA PLA2 contributed to cell injury
during chemical hypoxia in isolated rat hepatocytes (16, 17).
Mitochondrial injury is a critical step in cell death during
chemical hypoxia (18). Data from our laboratory as well as
others have demonstrated that products of PLA2 catalyzed
reactions can induce the mitochondrial permeability transition
(MPT), and reagents known to inhibit PLA2 activity can block
induction of the MPT in isolated mitochondria (19, 20). Thus,
the mitochondria appear to be a logical target of group IIA
PLA2 where it could induce the MPT and onset of cell death.
The recent discovery of other low molecular PLA2s (i.e. group
V PLA2) has drawn into question some of the functions previ-
ously attributed to group IIA PLA2 (2). For example, late phase
release of AA during mast cell activation was believed to be
mediated by group IIA PLA2, but has recently been found to be
normal in a cell line lacking demonstrable group IIA PLA2
activity (21). Certain reagents used to modulate group IIA
PLA2 activity such as inhibitors, antisense oligonucleotides,
and antibodies thought to be specific to group IIA PLA2, have
now been shown to act nonspecifically via group V PLA2. Given
these concerns, the most direct way of elucidating group IIA
PLA2 function is to study cellular phenotype changes after
expression of group IIA PLA2 and its mutants. In this study, we
generated cells stably expressing rat group IIA PLA2 and its
His-47 (a residue essential for its catalytic activity) to Gln
mutant (22). We found that the group IIA PLA2 generated
anti-apoptotic survival signals in BHK cells. This finding sheds
new light on the understanding of the function of group IIA
PLA2 in inflammation and other pathological processes.
EXPERIMENTAL PROCEDURES
Vectors and Reagents—Enhanced GFP (EGFP) fusion vector pEGFP-
N1, expression vector pIRES1neo, Quick Clone rat liver cDNA, and
ApoAlert DNA Fragmentation Assay Kit were purchased from CLON-
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TECH (Palo Alto, CA). Restriction enzymes were purchased from New
England Biolab (Beverly, MA). T4 DNA ligase and CELLTiter 96 Aque-
ous One Solution Cell Proliferation Assay were from Promega (Madi-
son, WI). The Expand High Fidelity PCR System and Apoptotic DNA
Ladder Kit were from Roche Molecular Biochemicals (Indianapolis, IN).
QIAprep Miniprep, QIAEX II Gel Extraction Kit, and SuperFect Trans-
fection Reagent were purchased from QIAGEN (Santa Clarita, CA).
BODIPY TR ceramide and MitoTracker Red CM-H2Xros were pur-
chased from Molecular Probes (Eugene, OR). 12-epi-Scaradial, aristolo-
chic acid, and lysophosphatidic acid were purchased from BIOMOL
(Plymouth Meeting, PA).
Vector Construction—The PCR amplification program used was as
follows: 94 °C 5 min, 50 °C 2 min, 72 °C, 3 min (first cycle); 94 °C 1 min,
50 °C 2 min, 72 °C, 3 min (30 cycles), 94 °C 1 min, 50 °C, 2 min, 72 °C
10 min (last cycle). To clone the sequence encoding the mature rat liver
group IIA PLA2 protein, PCR reaction was performed using upstream
primer F3B, 59-AATTCAGCTCGAGATGAGCCTTCTGGAGTTTGGGC-
AAATG-39 and downstream primer R1B, 59-CGAAGATGCTGCAGTA-
AGCAACTGGGCGTCTTCCCTTTGCAAAACTTGTTGGGGTAGAA-
C-39 and rat liver cDNA as template. The fragment was cut with
XhoI/PstI and inserted into pEGFP-N1. The resulting plasmid was
named pF3B. To clone the complete cDNA sequence of the rat group IIA
PLA2, PCR reaction was performed using upstream primer F5, 59-GA-
GAGCGGCCGCATGAAGGTCCTCCTGTTGCTAGCAGT-39 and down-
stream primer R1D, 59-GATGTCGAATTCAGCAACTGGGCGTCTTCC-
CTTTGC-39 and rat liver cDNA as template. The PCR fragment was
digested with NotI/EcoRI and inserted into pIRES1neo, resulting in
pPLA2. To create an in-frame fusion between the full-length PLA2 and
EGFP, PCR reaction was performed using upstream primer F4B 59-A-
ATTCAGCTCGAGATGAGCCTTCTGGAGTTTGGGCAAATG-39 and
downstream primer R1B and rat liver cDNA as template. The PCR
fragment was digested with PstI/XhoI, then cloned into PstI/XhoI sites
upstream of the N terminus of EGFP in pEGFP-N1. The resulting
plasmid was named pF4B. The PLA2-EGFP coding region was removed
by digestion with NdeI (a site in the CMV promoter upstream of the
PLA2-EGFP region) and NotI, and was cloned into pIRES1neo, result-
ing in pFPG. To construct MHIS that carries a His-473 Gln mutation
in PLA2 (22), we used the upstream primer MHISF 59-CAGAGGATC-
CCCCAAGGATGCCACAGATTGGTGCTGTGTGACTCAAGACTGTT-
GTTAC-39, which overlaps the single BamHI site in the PLA2 and
carried a CAT (His) to CAA (Gln), and the downstream primer MHISR
59-ATGGTGGCGACCGGTGGATCCCGGGCCCGC-39 and pF4B as
template in the PCR reaction. The fragment carrying the Gln mutation
was digested with BamHI and recovered from agarose gel. The His-47
in pF4B was then replaced with Gln using the following procedure:
pF4B was digested with BamHI to remove the fragment carrying His-
47. The remaining vector sequence (including part of the PLA2 se-
quence) was then ligated to the fragment carrying the mutation at
16 °C for 1 h. PCR was then performed using F4B and R1B as primers
with the ligation reaction as template. The fragment corresponding to
the correct size was recovered from the agarose gel, digested with
XhoI/PstI, and cloned into pEGFP-N1. The resulting plasmid was
named pMHIS. To clone the signal peptide sequence, PCR was per-
formed using primer SIGF 59-GTGTATCATATGCCAAGTACG-39 and
primer SIGR 59-CAGAATCTGCAGCCCAAACTCCAGAAGGCTCCCC-
TGGACCTGAATTGAG-39 and pFPG as template. The fragment was
recovered and digested with NdeI/PstI, then cloned into the correspond-
ing sites in pF4B, resulting in in-frame fusion with EGFP coding region.
The resulting plasmid was named pSIG/G. To generate the group IIA
PLA2 mutants carrying a His-47 3 Gln mutation, PCR was performed
using F5 and R1D primers and pMIHS template. The fragment was
cloned as described for pPLA2. In all the fusion proteins, the stop codon
of PLA2 (TGA) was changed to TTA which encodes a Leu residue. The
sequences of all PCR-derived constructs were confirmed.
Transfection—Baby hamster kidney (BHK) cells were cultured at
37 °C in 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Life
Technologies, Inc., Gaitherburg, MD) containing 10% fetal bovine se-
rum (FBS, Sigma). In some experiments, DMEM/F-12 (Life Technolo-
gies, Inc.) was used. For transient expression, cells were grown on
coverslips in a 35-mm culture dish to about 50% confluence. In a typical
transfection experiment, 2 mg of DNA was mixed with 100 ml of medium
(FBS- and antibiotic-free) and 25 ml of SuperFect Transfection Reagent
(QIAGEN) and incubated at room temperature for 30 min. 1 ml of
medium containing 10% FBS was added and the mixture immediately
added to the cells. Following incubation at 37 °C for 2 h, the cells were
washed with phosphate-buffered saline, then cultured in fresh medium.
EGFP fluorescence usually could be observed after overnight incuba-
tion. To obtain stable clones, Geneticin (500 mg/ml, Life Technologies,
Inc.) was added to medium 2–3 days post-transfection. The cells were
selected for 2 weeks.
RNA Isolation and Reverse Transcriptase (RT)-PCR—RNA was iso-
lated from cells using High Pure RNA Isolation Kit (Roche Molecular
Biochemicals) according to the manufacturer’s manual. RT-PCR was
performed using Access RT-PCR System (Promega). A 50-ml reaction
contained 25 ml of nuclease-free water, 10 ml of avian myeloblastosis
virus/Tf1 5 3 buffer, 1 ml of 10 mM dNTP mixture, 5 ml of F5 primer (4
mM), 5 ml of R1D primer (4 mM), 2 ml of 25 mM MgSO4, 1 ml of avian
myeloblastosis virus reverse transcriptase (5 units/ml), 1 ml of Tf1 DNA
polymerase (5 units/ml), and 2 ml of RNA. Reverse transcription was
carried out at 48 °C for 1 h. After incubation at 95 °C for 4 min to
inactivate reverse transcriptase, PCR amplification was performed us-
ing 95 °C 1 min, 60 °C 1 min, 70 °C 1 min for 30 cycles. The DNA was
separated on 1% agarose gel.
Fluorescent Microscopy—Final concentrations of the probes were 10
nM for MitoTracker and 15 mM for BODIPY TR ceramide. To stain
organelles, cells were cultured in medium containing the appropriate
probes for 10–30 min, then washed three times with phosphate-buff-
ered saline. The coverslips were then mounted on slides and sealed with
rubber cement. Fluorescence was examined with Olympus IX-70 micro-
scope and recorded with an ORCA100 CCD camera (Hamamatsu). The
filter settings for EGFP fluorescence were a 488/20 nm excitation band-
pass filter, a 495-nm dichroic mirror, and a 513/30 nm emission filter.
The filter settings for red fluorescence (MitoTracker, BODIPY TR cer-
amide) were a 530–550 nm excitation band-pass filter, a 570-nm di-
chroic mirror, and a 590-nm (long pass) emission filter.
Cell Viability and Apoptosis Detection—Cell viability was deter-
mined with CELLTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega) according the manufacture’s instruction. DNA ladders
were detected either with Apoptotic DNA Ladder kit (Roche Molecular
Biochemicals) or with partial lysis of plasma membrane with 0.5%
Triton X-100 with some modification (23) and preparing low molecular
DNA. TUNEL assay was performed using ApoAlert DNA fragmenta-
tion Assay Kit (CLONTECH).
RESULTS
Cloning and Characterization of Rat Group IIA PLA2—The
full-length sequence (including signal peptide) of secretory
group IIA PLA2 from rat platelets (secretory/membrane-asso-
ciated) is available in GenBank (accession number D00523).
Rat liver group IIA PLA2 has been reported to be localized in
mitochondria (12), and the sequence of the mature liver/mito-
chondrial group IIA PLA2 is also available in GenBank (acces-
sion number X74364). The sequence of these two proteins (rat
platelet secretory group IIA PLA2 versus rat liver group IIA
PLA2) differs by only 1 amino acid residue, i.e. Arg-94 in the
liver/mitochondrial group IIA PLA2 versus Ala-94 in the secre-
tory group IIA PLA2 (15, 24, 25).
Because the presequence of the mitochondrial group IIA
PLA2 has not been identified, it is unclear whether these two
proteins contain the same signal peptide, and whether group
IIA PLA2 can localize to both mitochondria and secretory path-
ways. Based on the N- and C-terminal sequence of the liver/
mitochondrial group IIA PLA2, we cloned the cDNA sequence
encoding mature PLA2 from rat liver by PCR amplification.
The sequence we cloned was identical to that of the secretory
group IIA PLA2 including an Ala at position 94. It is likely that
the inaccuracy of earlier versions of Taq polymerase caused the
previously reported difference in the sequence of mitochindrial
versus secretory PLA2. Using primers corresponding to the
signal peptide sequence of the secretory PLA2 and the COOH
terminus of mitochondrial/secretory group IIA PLA2, we am-
plified the full-length cDNA sequence of the group IIA PLA2
from rat liver. The sequence, including signal peptide, was
again identical to that of the rat secretory group IIA PLA2. We
then examined whether there were any alternatively spliced
forms of group IIA PLA2 that may bear different prese-
quence/or signal peptide. Using primers corresponding to the 59
terminus of the primary transcript (PSTART in Fig. 1A) (26)
and to the C terminus of mitochondrial/secretory group IIA
PLA2 (R1B) to amplify any possible alternatively spliced
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mRNAs, only one band was detected in the reaction product
(Fig. 1B). To examine whether this band contained more than
one DNA fragment, the band was recovered and subjected to
direct sequencing using PSTART and R1B as primers. No het-
erogeneity was found (Fig. 1C). Therefore, we conclude that
there is only one group IIA PLA2 molecule in rat liver. The data
also indicate that before post-translational processing, mito-
chondrial group IIA PLA2 bears the same signal peptide as the
secretory group IIA PLA2 does.
To examine whether rat liver group IIA PLA2 targets to
mitochondria, we fused the N-terminal 29 residues (including
the 21-residue signal peptide and 8 residues of the mature
enzyme) to the N terminus of EGFP (SIG/G in Fig. 2). When
expressed in BHK cells, the SIG/G fusion protein localized
mainly at one pole of the nucleus (Fig. 3B), which is character-
istic for the Golgi body. In contrast, when expressed alone
EGFP was evenly distributed in the cytosol (Fig. 3A). In some
cells, fusion proteins were also found in typical secretory or-
ganelles, including Golgi stacks (Fig. 3C), vesicles detaching
from Golgi body (Fig. 3D), endoplasmic reticulum (Fig. 3E), and
vesicles (Fig. 3F). This reflects the different stages of secretory
protein undergoing the maturation-secretion process.
We also generated fusion proteins composed of the full-
length rat group IIA PLA2 (including signal peptide) and EGFP
(FPG or MHIS in Fig. 2). MHIS is identical to FPG except it
contains a His-47 3 Gln mutation. When expressed in BHK
cells, these fusion proteins also displayed a distribution pattern
typical for a secretory protein. Fig. 4, A and B (FPG) and C
(MHIS), show the fusion protein localized mainly in vesicles.
Fig. 4, D-F (FPG), show the localization of FPG fusion protein
in the Golgi body. Fig. 4, G-I (FPG), demonstrate that the
fusion protein does not localize in mitochondria. From these
results, it is concluded that the rat liver group IIA PLA2 is a
secretory protein. Therefore, during cell injury, group IIA PLA2
cannot directly regulate mitochondrial function and induce the
MPT. Thus, all of the physiological effects elicited by rat liver
group IIA PLA2 should be considered as the result of its inter-
action on the membranes of the secretory pathways, and in
particular, the plasma membrane.
FIG. 2. Gene constructs. SIG, signal peptide. H47Q, His-47 3 Gln
mutation.
FIG. 3. SIG/G fluorescence. A, cells transfected with pEGFP-N1
(control). B-F, cells transfected with pSIG/G. A was taken with 3 10
objective lens; B with 3 20; C-F with 3 100.
FIG. 1. Examination of alterna-
tively spliced mRNA by PCR. A,
genomic structure of rat group IIA PLA2
gene. Primers, transcription initiation
site, and intron 1 are indicated by arrows.
Exons are shown as boxes. B, agarose gel
(1%) electrophoresis of PCR products. C,
sequence of the fragment recovered from
the gel (PSTART primer). MW, l/HindIII
DNA.
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Group IIA PLA2 Generates Anti-apoptotic Survival Signals
in BHK Cells—To study the biological function of the secretory
group IIA PLA2, we generated cells stably expressing this gene.
For this purpose, we used a bicistronic expression system
(pIRES1neo, CLONTECH). In this system, a single cytomega-
lovirus promoter directs the transcription of mRNA consisting
of both the group IIA PLA2 and the selection marker neo
r. The
group IIA PLA2 is located upstream of neo
r in the bicistronic
transcript. Because the two genes are simultaneously ex-
pressed, after transfection and selection nearly all the G418-
resistant cells express the group IIA PLA2. This allowed us to
rapidly obtain a pool of PLA2 expressing cells without cloning.
A total of 35 G418-resistant clones were obtained. After har-
vesting and pooling of these cells (NP), the expression of rat
group IIA PLA2 was confirmed (Fig. 5A). To our surprise, stable
expression of group IIA PLA2 was not associated with cytotox-
icity. In fact, when cultured in serum-free medium, normal
BHK cells underwent massive apoptosis, while apoptosis in the
NP cells was significantly lower (Fig. 5B).
To examine whether resistance to apoptosis of the NP cells
was due to expression of the rat group IIA PLA2, we generated
a mutant PLA2, in which His-47, the residue essential for the
hydrolytic activity (by binding of an H2O molecule to the cata-
lytic center) of PLA2, was mutated to Gln (Fig. 2) (22). A pool of
cells (HQ) expressing the His-47 mutant was obtained using
the same method as described for the NP cells, and the expres-
sion of the mutant PLA2 was confirmed (Fig. 5A). As shown in
Fig. 5, C and D, the HQ cells underwent massive apoptosis
after withdrawal of FBS.
We then compared the viability of BHK, HQ, and NP cells in
medium lacking growth factors. Fig. 6, A-C, show NP cells
survived better than BHK and HQ cells in serum-free medium.
Morphological changes observed in serum-free medium is also
more substantial for normal BHK and HQ cells compared with
NP cells (Fig. 6D).
If resistance to apoptosis of NP cells is caused by rat group
IIA PLA2 expression, then secretory PLA2 inhibitors should be
able to abrogate this effect. 12-epi-Scalaradial (SCA) is a spe-
cific inhibitor for secretory PLA2 (27–29). A dose-dependent
inhibition of cell survival in serum-free medium was found in
NP cells in the presence of SCA (Fig. 7A). SCA also inhibited
the survival of BHK and HQ cells. A possible explanation is
that it might abrogate the endogenous sPLA2 function. Another
widely used PLA2 inhibitor, aristolochic acid (ArA) (30–32),
also abrogated the survival effect in NP cells (Fig. 7B). In the
presence of FBS, these inhibitors did not have significant ef-
fects on cell survival (Fig. 7, C and D). Taken together, these
results strongly suggest that expression of rat group IIA PLA2
produces survival signals in this model system.
Group IIA PLA2 is also known to generate lipid mediators
including AA and LPA (5). To study whether they might medi-
ate group IIA PLA2 survival activity in the NP cells, we treated
the NP cells with LPA and AA. At high concentration (30 mM),
AA itself induced cell death. At lower concentration, AA did not
have apparent protective effects (data not shown). Similarly,
LPA did not have any protective effect in either BHK or HQ
cells, but it did increase cell survival of NP cells (Fig. 7E).
Therefore, neither AA nor LPA can replace the signals elicited
by rat group IIA PLA2.
DISCUSSION
The major goal of our study was to elucidate the role of rat
liver group IIA PLA2 in apoptosis induced by serum starvation.
It is known that increased group IIA PLA2 expression is asso-
FIG. 4. Localization of FPG and
MHIS fusion protein. A (FPG), B (FPG),
and C (MHIS) show the fusion proteins in
vesicles rather that mitochondria. D
(FPG), E (BODYPI TR ceramide), and F
(overlaid fluorescence of D and E) show
the localization of FPG in Golgi body. G
(FPG), H (MitoTracker), and I (overlaid
fluorescence of G and H) show that the
protein does not localize in mitochondria.
A was taken with 3 10 objective lens, and
all others with 3 100.
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ciated with hypoxia/reperfusion injury in rat hepatocytes (16,
17), and that the products of PLA2-catalyzed reactions can
induce the MPT in isolated mitochondria. In addition, a num-
ber of papers have proposed that mitochondrial PLA2 might
induce the MPT following a variety of insults (33–35). These
data, in conjunction with the report detailing the biochemical
purification of mitochondrial localized group IIA PLA2 from rat
liver 10 years ago (12), support the hypothesis that group IIA
FIG. 5. Detection of the rat group
IIA PLA2 expression and apoptosis. A,
detection of rat group IIA PLA2 expres-
sion in BHK, HQ, and NP cells by RT-
PCR. B, DNA ladder. BHK and NP cells
were recovered by trypsin digestion. After
washing twice with serum-free medium,
2 3 106 cells were plated into 35-mm
dishes with DMEM/F12 medium and
0.5% FBS. After 3 days, DNA was isolated
using Apoptotic DNA ladder kit and re-
solved on 1.2% agarose gel. MW1, l/Hin-
dIII marker. C, DNA ladder. After wash-
ing twice with serum-free medium, 107
cells were plated into 90-mm dishes in
DMEM/F12 medium and 1% FBS. 24 h
later, the cells were washed once with
serum-free medium, and cultured in se-
rum-free medium for 24 h. DNA ladder
was prepared by Triton X-100 lysis. MW2,
123-base pair DNA ladder. D, TUNEL as-
say. HQ cells were washed twice with me-
dium then plated onto glass coverslip in
DMEM/F-12 medium and 1% FBS. 24 h
later, the cells were washed once with
medium, and cultured in serum-free me-
dium. After overnight culture, DNA frag-
mentation was detected with ApoAlert
DNA Fragmentation Assay Kit (CLON-
TECH). a, fluorescent image (show DNA
fragmentation). b, transmitted light im-
age (3 40 objective lens).
FIG. 6. Cell viability after deprivation of growth factors. A-C, 24–72 h viability. BHK, HQ, and NP cells were washed twice with serum-free
medium, then plated into 96-well plate at 4 3 104 cells/well in DMEM/F-12 and 1% FBS. 24 h later, the cells were washed once with serum-free
medium and cultured in either serum-free medium or supplemented with 5% FBS. The cell viability was determined with CELLTiter 96 AQueous
One Solution Cell Proliferation Assay. D, cell morphology (3 10 objective lens) 8 h after serum withdraw. The experiments were done in triplicate.
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PLA2 is part of the injury pathway in cells and exerts this
injury promoting activity by targeting the mitochondria. How-
ever, it has generally been accepted that mammalian group IIA
PLA2 can be both a secretory and mitochondrial protein (2, 3,
12–14), and to date, most work aimed at elucidating the activ-
ity of group IIA PLA2 have focussed on secretory group IIA
PLA2. Because of this, we decided to visualize the location of
this PLA2 in normal and stressed cells using an EGFP-PLA2
fusion protein to determine whether mitochondria are a target
of group IIA PLA2.
We cloned group IIA PLA2 from rat liver (reportedly localized
in mitochondria (12)), and the sequence we cloned was identical
to secretory group IIA PLA2. Furthermore, we did not find any
alternatively spliced variants of the primary transcript of
group IIA PLA2 that might generate a different signal peptide.
These results indicate that there is only one type of group IIA
PLA2 molecule in rat liver.
We then studied the subcellular localization of the rat group
IIA PLA2. To accomplish this, we used EGFP as a tag to follow
the maturation and intracellular location of the fusion protein
in living cells. This method has been demonstrated to work for
both secretory and mitochondrial proteins (36–38). To our sur-
prise, EGFP fusion protein consisting of either the signal pep-
tide or full-length sequence of group IIA PLA2 was found ex-
clusively localized to the secretory pathways, but never in
mitochondria. This distribution pattern is not cell-type (BHK)
specific, as similar results were obtained in the mouse hepato-
cyte cell line AML12 (data not shown). Taken together, these
data indicate that group IIA PLA2 is not a mitochondrially
localized protein. It is therefore unlikely that group IIA PLA2
has any direct role in regulating mitochondrial function and
onset of the MPT.
FIG. 7. PLA2 inhibitors and LPA on cell survival in serum-free medium. A, SCA. B, ArA. C, SCA plus serum. D, ArA plus serum. E, LPA.
The cells were plated into 96-well plates and washed 24 h later as described in the legend to Fig. 6. The cells were then treated with the SCA, ArA,
SCA 1 FBS, ArA 1 FBS for 24 h, or with LPA for 96 h, then the viability was determined. In FBS 1 SCA/or 1 ArA treatment, 10% FBS was used.
The experiments were done in triplicate.
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Secretory group IIA PLA2 is believed to regulate a number of
physiological as well as pathological processes by generating
AA and other lipid mediators. High levels of group IIA PLA2
have been found at inflammatory sites and increased serum
group IIA PLA2 levels are thought to be related to the severity
of sepsis (39–41). In isolated hepatocytes, expression of group
IIA PLA2 was up-regulated during chemical hypoxia and its
contribution to hypoxic injury has been demonstrated (17).
Despite numerous in vitro data that suggest the important role
of the group IIA PLA2 in inflammation and cell injury, it should
be noted that in vivo models of injury have not always sup-
ported such a destructive role for group IIA PLA2. For example,
transgenic mice expressing high levels of group IIA PLA2 do
not develop any overt inflammatory conditions. No abnormal-
ities were found in any tissue other than skin, where alopecia,
epidermal hyperplasia, adnexal hyerplasia, and hyperkeratosis
were observed (42). Several mouse strains have been found to
contain a frameshift mutation in group IIA PLA2, resulting in
loss of the enzyme activity. Infection of group IIA PLA2 (2/2)
mice (C57BL/6) with Helicobacter felis, a gastroduodenal
pathogen, lead to increased apoptosis and proliferation com-
pared with group IIA PLA2 (1/1) BALB/c and C3H/HeJ mouse
(43). Much more marked inflammatory and proliferative re-
sponse to H. felis was also observed in another group IIA PLA2
(2/2) mouse SV129 than in PLA2 (1/1) mice (43). No satisfac-
tory explanation has been proposed for this contradiction. One
possible reason is that sPLA2 contributes to some extent in the
destruction of pathogen in PLA2 (1/1) mice.
During the course of these studies, we noted that cells stably
expressing group IIA PLA2 were more resistant to apoptosis
induced by serum starvation. This protective role of group IIA
PLA2 in serum withdrawal-induced apoptosis was further con-
firmed using a number of other approaches including PLA2
inhibitors and site-directed mutagenesis of group IIA PLA2
His-47. Because the lipid mediators AA and LPA could not
mimic the effects of group IIA PLA2, it appears that other
mechanisms are responsible for the protective physiological
function of group IIA PLA2. Interestingly, although LPA had no
effect in BHK and HQ cells, it did promote survival in NP cells.
As LPA can transduce survival signals via phosphatidylinositol
3-kinase (43, 44), it is possible that the group IIA PLA2 and
LPA might synergistically transduce survival signals in
fibroblasts.
How group IIA PLA2 generates survival signals remains to
be elucidated. Group I PLA2 can stimulate cell proliferation by
binding to a receptors (45). Whether group IIA PLA2 has its
own receptors or can bind to group I PLA2 receptors of BHK
cells is unknown. Given the similarity between group I and IIA
PLA2, it is possible that group IIA PLA2 may activate a sur-
vival pathway by a similar mechanism. If so, this might also
explain why PLA2 possesses some functions independent of its
hydrolytic activity.
Secretory PLA2 has been identified as enhancing factor that
enhances the binding of epidermal growth factor to cells (47). It
is possible that rat group IIA PLA2 may trigger anti-apoptotic
signaling via epidermal growth factor. Alternatively, group IIA
PLA2 may affect the receptor signaling via modifying mem-
brane topology.
The anti-apoptotic activity of group IIA PLA2 also may ex-
plain the pathogenesis of certain clinical diseases. It has been
reported that the use of certain Chinese herbs containing aris-
tolochic acid for weight loss may cause severe renal failure (48).
As aristolochic acid inhibits group IIA PLA2 activity, it seems
likely that aristolochic acid inhibition of PLA2-mediated signal-
ing may contribute to the renal injury seen in these patients.
The immunosuppressive drug cyclosporin A has the well
known side effect of nephrotoxicity (49). Cyclosporin A has been
shown to down-regulate mRNA level of group IIA PLA2 in
mesangial cells (50). If group IIA PLA2 generates anti-apo-
ptotic signals in kidney, long-term use of cyclosporin A may
impair group IIA PLA2-medited survival signal transduction.
Group IIA PLA2 is transcriptionally up-regulated by inflam-
matory cytokines, partially via NFkB (50). NFkB is believed to
protect against tumor necrosis factor-induced cell death by
inducing the expression of anti-apoptotic genes (51). High lev-
els of group IIA PLA2 is present at inflammatory sites, and the
physiological role of the protein in inflammation remains
largely unknown. Our results suggest the possibility that group
IIA PLA2 might counteract the effects caused by some pro-
inflammatory cytokines, such as tumor necrosis factor that
promotes cell death.
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